Key result
Canakinumab reduces major cardiovascular events in post-MI patients without adverse clinical renal events.
Why the study?
Does canakinumab reduce cardiovascular events in stable post-myocardial infarction patients with elevated hsCRP and chronic kidney disease?
RCT (n=10,061)
randomly allocated
Does canakinumab reduce cardiovascular events in stable post-myocardial infarction patients with elevated hsCRP and chronic kidney disease?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“This dose-finding data will also inform the design of a hard outcomes trial to test the hypothesis that IL-6-lowering will reduce cardiovascular event rates in patients with chronic kidney disease, which is based upon an observation in an 1800 patient CKD subset of the CANTOS trial.”
Inhibition of IL-1β with canakinumab reduces major adverse cardiovascular events in high-risk atherosclerosis patients with CKD without causing adverse renal events.
BACKGROUND: Inflammation contributes to chronic kidney disease (CKD), in part mediated through activation of interleukin (IL)-1β by the NLRP3 inflammasome within the kidney. This process also likely contributes to the accelerated atherosclerosis associated with nephropathy. OBJECTIVES: The authors hypothesized that canakinumab, a human monoclonal antibody targeting IL-1β, might reduce cardiovascular event rates and improve renal function among post-myocardial infarction patients with CKD. METHODS: Stable post-myocardial infarction patients with high-sensitivity C-reactive protein (hsCRP) ≥ 2mg/l were randomly allocated to placebo or to 1 of 3 doses of canakinumab (50, 150, or 300 mg) given subcutaneously once every 3 months. Participants were followed for incident myocardial infarction, stroke, hospitalization for unstable angina requiring urgent revascularization, cardiovascular death, or death from any cause over a median follow-up period of 3.7 years (maximum 5 years). All patients additionally had serial monitoring of estimated glomerular filtration rate (eGFR), creatinine, the urine albumin to creatinine ratio (uACR), and were monitored for adverse renal and urinary events. CONCLUSIONS: IL-1β inhibition with canakinumab reduces major adverse cardiovascular event rates among high-risk atherosclerosis patients with CKD, particularly among those with a robust anti-inflammatory response to initial treatment. These cardiovascular benefits accrued with no adverse clinical renal events. (Canakinumab Anti-inflammatory Thrombosis Outcomes Study [CANTOS]; NCT01327846).
No takes yet. Share an insight, caveat, or question.
Ridker et al. (2018) conducted an RCT in Chronic Kidney Disease (n=10,061). Canakinumab vs. Placebo was evaluated on Incident myocardial infarction, stroke, hospitalization for unstable angina requiring urgent revascularization, cardiovascular death, or death from any cause. Among 10,061 post-myocardial infarction patients (1,875 with CKD), canakinumab reduced major adverse cardiovascular event rates without adverse clinical renal events.
Synapse has enriched 10 related papers. Consider them for comparative context: